21 results about "Rhinovirus" patented technology

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.

The application provides a quality control for detecting respiratory pathogen nucleic acid, which comprises any one or more of the following respiratory pathogens: coronavirus, influenza virus, adenovirus, Mycoplasma pneumoniae, Streptococcus pneumoniae, rhinovirus or / and Legionella pneumophila. The full-length genome sequence of the coronavirus is divided into 6 target fragments, each with a length of 4000-5500 bp. The quality control of the application covers all detection target sequences (or target points) of the coronavirus, has a wide coverage, comprehensively detects target points, and does not have the phenomenon of missed detection. The quality control of the application contains main respiratory pathogen infections, has a wide range, and uses real virus samples and lentivirus samples as raw materials, and has more accurate detection target points. The preparation of the coronavirus quality control of the application integrates the target gene sequence into the host genome through the lentivirus vector, knocks out the self-replication gene in the preparation process, and has a "self-inactivation" ability, so that the recombinant lentivirus cannot replicate in the target cells and infect other cells.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

The present invention relates to a bifunctional peptide comprising a virus-binding portion (2) and a mucin-binding portion (1) covalently linked to the virus-binding portion (2). The virus-binding portion is selected from peptides that bind to SARS-CoV-2, influenza A virus, influenza B virus, rhinovirus and other enteroviruses, human parainfluenza virus, and / or metapneuvirus. The mucin-binding portion is selected from lectins such as trefoil factor 3.

Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and / or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-COV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

The invention belongs to the field of biological medicine, and discloses a broad-spectrum anti-enterovirus peptidomimetic 2CA-1 targeting enterovirus 2C protein and application of the broad-spectrum anti-enterovirus peptidomimetic 2CA-1. The 2CA-1 can be accurately butted to 2C protein binding pockets of EV71 and CVB3, the helicase activity of the 2CA-1 is effectively inhibited, and the 2CA-1 shows a strong and broad-spectrum antiviral effect on various pathogens such as coxsackie virus, EV-D68 and rhinovirus on the cellular level. More importantly, the 2CA-1 realizes a druggability breakthrough of excellent oral bioavailability in an animal model, and the in-vivo virus load can be remarkably reduced after oral administration. The invention provides an antiviral candidate drug with high-efficiency broad-spectrum activity and ideal oral administration characteristics, and has a wide application prospect.

The invention relates to the technical field of biological detection, in particular to a primer and probe combination for joint detection of seven pathogens, a kit and application. The primer and probe combination comprises primers and probes for specifically detecting the following pathogens: novel coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus, mycoplasma pneumoniae, rhinovirus and adenovirus, and nucleotide sequences are shown as SEQ ID NO: 1-24. Based on the primer and probe combination of the multiple system, seven targets can be simultaneously detected in one sample within 30 minutes. In addition, the sensitivity of the multiple systems is high, and the lowest detection limit is 500 copies / mL; and the kit has good specificity and has no cross reaction with other pathogens causing the same symptom. In addition, a PCR reagent comprising the primer and probe combination can be freeze-dried, a nucleic acid elution product to be detected is adopted to redissolve the PCR reagent during detection, and closed amplification is performed on a micro-fluidic chip.

Compounds and treatment methods with dipeptidyl compounds exhibiting antiviral activity and / or inhibition of viral replication against viruses by inhibiting 3CL protease, particularly those belonging to picornavirus, the compounds having a formula:(I) or (I)*.

The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.

The invention relates to the technical field of biological detection, in particular to an LAMP primer composition, an HRV detection system, a kit for rapidly detecting human rhinoviruses and application, the LAMP primer composition comprises an outer primer pair, an inner primer pair and a loop primer pair, the outer primer pair comprises the human rhinoviruses F3 and the human rhinoviruses B3, the inner primer pair comprises the human rhinoviruses FIP and the human rhinoviruses BIP, and the loop primer pair comprises the human rhinoviruses F3 and the human rhinoviruses B3. The loop primer pair comprises a human rhinovirus LF and a human rhinovirus LB, the HRV detection system comprises the LAMP primer composition, and the kit comprises the HRV detection system. The LAMP primer composition with the optimal performance, the HRV detection system and the kit for rapidly detecting the human rhinovirus are provided for the first time, when the LAMP primer composition is used for detecting the HRV, the reaction time is only 15 minutes, the detection sensitivity is 200 copies / mL, and the LAMP primer composition has the advantages of being easy and convenient to operate, low in cost and the like and is suitable for rapid on-site detection.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The present invention provides methods for identifying the amino acid sequence of a native polyprotein from a group A or C rhinovirus that can be used as an immunogen capable of eliciting an immune response against rhinoviruses from multiple serotypes within the same group. The present invention also provides immunogenic compositions comprising at least one mRNA comprising a non-native, optimized nucleic acid encoding a polyprotein identified by this method.

The application discloses a construction method of Aedes albopictus Aa01 cell line and susceptible cell model of Decapod iridovirus 1, and belongs to the technical field of virology and aquaculture disease prevention and control, wherein the Aedes albopictus Aa01 cell line is preserved in the China Center for Type Culture Collection of Wuhan University, and the preservation number is CCTCC NO: C202648. The method for constructing the DIV1 susceptible cell model based on the above cell line comprises the following steps: culturing the Aedes albopictus Aa01 cell line, and subculturing or using for virus inoculation when the density reaches 80%-90%; inoculating the DIV1 into the Aedes albopictus Aa01 cell line, removing the virus liquid after virus adsorption, and adding cell maintenance liquid for continuous culture; and observing the cytopathic effect CPE, collecting the cell culture when the CPE reaches 70%-80%, and obtaining the amplified DIV1 virus liquid. The DIV1 susceptible cell model constructed by the method can solve the problem that there is currently a lack of stable and continuously subcultured DIV1 in vitro culture.

The present invention provides a method for identifying the amino acid sequence of a naturally occurring polyprotein from a group A or C rhinovirus that can be used as an immunogen capable of eliciting an immune response against rhinoviruses from multiple serotypes within the same group. The invention also provides immunogenic compositions that comprise at least one mRNA comprising a non-naturally occurring optimized nucleic acid encoding a polyprotein identified by this method.

This article describes the use of phenol in the treatment of microbially induced dyspnea, specifically viral dyspnea, in a human patient, where the phenol is administered parenterally. The dyspnea is associated, in particular, with Acute Respiratory Distress Syndrome (ARDS). The viral infection is caused, in particular, by a virus selected from the group consisting of coronaviruses, influenza, Ebola, respiratory syncytial virus, HIV, Lassa virus, and rhinovirus. The phenol is administered parenterally, specifically subcutaneously or intravenously.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

The invention discloses a human rhinovirus susceptibility evaluation method and device, electronic equipment and a storage medium, which are used for solving the technical problem that the currently adopted human rhinovirus detection method cannot evaluate the human rhinovirus susceptibility of an individual in advance. The method comprises the following steps: acquiring a baseline blood transcriptome of a subject queue and a real susceptibility condition of a human rhinovirus; performing characteristic gene screening on the baseline blood transcriptome based on differential expression analysis and multi-dimensional joint interaction analysis to obtain a characteristic genome; extracting expression quantity data of a feature genome from the baseline blood transcriptome as a feature data set, and training a double-layer susceptibility evaluation model based on the feature data set and a real susceptibility condition; acquiring a to-be-detected baseline blood transcription sample, and extracting expression quantity data of the characteristic genome from the to-be-detected baseline blood transcription sample as a to-be-detected sample; and inputting a to-be-detected sample into the double-layer susceptibility evaluation model for human rhinovirus susceptibility prediction to obtain a susceptibility evaluation result.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

A method is provided for reducing cytokine secretion in virus-infected cells through treatment with specific alkylamides. The method includes identifying a cell infected with a rhinovirus or influenza virus and administering one or more alkylamides, such as Dodeca-2(E),4(E)-Dienoic acid isobutylamide, to reduce cytokine release, particularly interleukin-8 (IL-8). In certain embodiments, the alkylamides are in purified form and may be derived from Echinacea purpurea. The method may further comprise measuring IL-8 secretion to assess efficacy of the treatment. Another aspect provides a screening method for identifying specific alkylamides effective against respiratory virus infections by comparing cytokine secretion levels between infected cells treated with purified alkylamides and those treated with Echinacea purpurea ethanolic extract. Alkylamides demonstrating reduced cytokine secretion and a selectivity index greater than 10 are identified as therapeutic candidates for mitigating cytokine-mediated inflammatory responses in respiratory viral infections.

The invention provides a kit for detecting six respiratory pathogens by using a fluorescent PCR method, the kit is used for detecting the six respiratory pathogens by using a Taqman fluorescent probe multiple amplification technology, and the kit comprises a nucleic acid reaction solution A and a nucleic acid reaction solution B. The nucleic acid reaction solution A is used for detecting adenovirus, mycoplasma pneumoniae and human metapneumovirus, and the nucleic acid reaction solution B is used for detecting adenovirus, mycoplasma pneumoniae and human metapneumovirus. The nucleic acid reaction liquid B is used for detecting parainfluenza virus, rhinovirus and respiratory syncytial virus. The composition provided by the invention is high in detection accuracy, and 100 clinical samples detected by the kit provided by the invention are consistent with clinical results, indicating that the composition provided by the invention has very high accuracy. The method is high in detection specificity, and the detection result is visual and easy to interpret. Clinical doctors are assisted to judge respiratory tract pathogen infection more comprehensively and more accurately.